Cromwell Holdings LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Cromwell Holdings LLC has significantly reduced its stake in Thermo Fisher Scientific Inc. by 79.7%, now holding only 223 shares after selling 877 shares in the second quarter.
• Several institutional investors have recently increased their stakes in TMO, with notable investments including Nuveen LLC at approximately $532.4 million and Cohen Investment Advisors LLC boosting their stake by 6,655.5%.
• Thermo Fisher Scientific reported quarterly earnings of $5.36 per share, surpassing estimates, and has set its guidance for Q3 2025 EPS between $5.460 and $5.510.

Cromwell Holdings LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 79.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 223 shares of the medical research company's stock after selling 877 shares during the quarter. Cromwell Holdings LLC's holdings in Thermo Fisher Scientific were worth $91,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in TMO. Nuveen LLC purchased a new stake in Thermo Fisher Scientific in the 1st quarter valued at approximately $532,360,000. Sarasin & Partners LLP purchased a new stake in Thermo Fisher Scientific in the 1st quarter valued at approximately $187,134,000. EdgePoint Investment Group Inc. purchased a new stake in Thermo Fisher Scientific in the 1st quarter valued at approximately $172,139,000. Cohen Investment Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock worth $167,271,000 after acquiring an additional 331,180 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TMO. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Evercore ISI decreased their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. HSBC reissued a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, UBS Group lifted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $585.37.

Thermo Fisher Scientific Trading Down 1.1%

Shares of TMO opened at $525.07 on Friday. The stock has a fifty day moving average of $481.27 and a two-hundred day moving average of $447.60. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market capitalization of $198.27 billion, a PE ratio of 30.37, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $611.49.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last ninety days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.